Clinical trials: Bile Duct Neoplasm
Common Bile Duct Diseases, Common Bile Duct Calculi
Effects of Dexamethasone on Common Bile Duct Cannulation Time
The main aim of this clinical trial is to evaluate the effects of dexamethasone on common bile duct cannulation time during endoscopic retrograde cholangiopancreatography (ERCP) in patients with biliary pathologies.
- Conditions
- Common Bile Duct Diseases, Common Bile Duct Calculi, Common Bile Duct Stricture, Common Bile Duct Neoplasms
- Trial name
- NCT05945797
- Testing
- Dexamethasone 4mg
- Where
- Pakistan
- Volunteers
- 80 people
- Sponsor
- Gujranwala medical college District Headquarters Hospital, Gujranwala
Pancreatic Cancer, Common Bile Duct Diseases
A Prospective Study on the Safety and Efficacy of Robot-assisted Pancreaticoduodenectomy
Further studies are needed to investigate the prognosis and perioperative safety of patients undergoing robotic-assisted pancreaticoduodenectomy.
- Conditions
- Pancreatic Cancer, Common Bile Duct Diseases, Periampullary Carcinoma
- Trial name
- NCT05755594
- Testing
- Robot-assisted Pancreaticoduodenectomy
- Volunteers
- 100 people
- Sponsor
- The First Affiliated Hospital of University of South China
Anal Cancer, Colorectal Cancer
Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Anal Cancer, Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer
- Trial name
- NCT00003427
- Testing
- irinotecan hydrochloride, oxaliplatin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Melanoma, Non Small Cell Lung Cancer
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
AI-061 is a co-formulation drug product (DP) consisting of 1:1 ratio mix of AI-025, an anti-PD-1 antibody, and ONC-392, an anti-CTLA-4 antibody.
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, High Grade Serous Adenocarcinoma of Ovary
- Trial name
- PRESERVE-009 (NCT05858736)
- Testing
- AI-061
- Where
- 5 sites in Australia
- Volunteers
- 18 people
- Sponsor
- OncoC4, Inc.
Choledocholithiasis, Cholangiocarcinoma
Etomidate vs. Midazolam for Sedation During ERCP
Recently up-coming drug, etomidate which is a modulator of GABA(gamma-Aminobutyric acid)-A receptor has been known that it maintains the appropriate sedative levels and affects little effects on respiratory system.
- Conditions
- Choledocholithiasis, Cholangiocarcinoma, Pancreatitis, Pancreatic Cancer
- Trial name
- NCT02027311
- Testing
- Etomidate, Midazolam, Meperidine
- Where
- South Korea
- Volunteers
- 63 people
- Sponsor
- Cheju Halla General Hospital
Cancer of the Bile Duct, Gallbladder Cancer
Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer
The purpose of this clinical trial is to determine whether the combination of the established chemotherapeutic agent 5-fluorouracil(5-FU) and the large carbohydrate molecule GM-CT-01 is beneficial in treating advanced gall…
- Trial name
- NCT00386516
- Testing
- GM-CT-01, 5-Fluorouracil
- Where
- 3 sites in United States
- Sponsor
- Galectin Therapeutics Inc.
Breast Cancer, Colorectal Cancer
Biological Therapy in Treating Patients With Metastatic Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase I trial to study the effectiveness of biological therapy in treating patients who have…
- Conditions
- Breast Cancer, Colorectal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT00004604
- Testing
- CEA RNA-pulsed DC cancer vaccine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Duke University
Bile Duct Adenocarcinoma, Stage III Intrahepatic Cholangiocarcinoma
Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery
This phase I trial studies the side effects of capecitabine and Y-90 radioembolization in treating patients with bile duct cancer in the liver that has spread to other places in the body and cannot be removed by surgery.
- Conditions
- Bile Duct Adenocarcinoma, Stage III Intrahepatic Cholangiocarcinoma, Stage IVA Intrahepatic Cholangiocarcinoma, Stage IVB Intrahepatic Cholangiocarcinoma
- Trial name
- NCT03117855
- Testing
- Capecitabine, Laboratory Biomarker Analysis, Radioembolization
- Where
- United States
- Sponsor
- City of Hope Medical Center
Bile Duct Stricture, Bile Duct Cancer
PTFE Stents for Treatment of Malignant Biliary Strictures
In this randomized trial two two self-expanding metal stents (SEMS) for treatment of malignant biliary strictures are investigated.
- Conditions
- Bile Duct Stricture, Bile Duct Cancer, Pancreas Cancer
- Trial name
- NCT03763214
- Testing
- Stenting with PTFE-coated stent (HILZO)
- Where
- Germany
- Volunteers
- 64 people
- Sponsor
- Johannes Vermehren
Hilar Cholangiocarcinoma
Treatment of Non-resectable Bile Duct Cancer with Radiofrequency Ablation or Photodynamic Therapy
Bile duct cancer is often diagnosed after curative options are no longer available. Stent therapy is used to keep the ducts open and can be combined with photodynamic therapy (PDT) to extend life expectancy.
- Trial name
- CARP (NCT05551299)
- Testing
- Photosensitizer, Radiofrequency ablation (RFA)
- Where
- 20 sites in Germany
- Volunteers
- 258 people
- Sponsor
- University of Leipzig
Primary Sclerosing Cholangitis (PSC)
Cholangioscopy in Primary Sclerosing Cholangitis (PSC)
To demonstrate the clinical utility of the addition of per oral cholangioscopy (POCS) to standard endoscopic retrograde cholangiopancreatography (ERCP) with brushing cytology for diagnosis and early detection of…
- Trial name
- NCT03766035
- Testing
- SpyGlass DS I - II
- Where
- 6 sites in United States, Canada and 2 more
- Volunteers
- 43 people
- Sponsor
- Boston Scientific Corporation
Pancreatic Adenocarcinoma, Cholangiocarcinoma
The Future Management of Patients With Neoplasms of the Gastro-intestinal Tract
The aim of the present study is to research histological and molecular markers in patients with neoplasia of the gastrointestinal tract.
- Conditions
- Pancreatic Adenocarcinoma, Cholangiocarcinoma, Colon Cancer
- Trial name
- SOCRATE (NCT06728358)
- Testing
- Molecular analyses
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Bile Duct Neoplasms Malignant
Stenting Malignant Jaundice for Quality of Life
Endoscopic stent insertion is considered the method of choice for palliation of malignant bile duct obstruction (MBDO). However, it can cause complications and requires periodic stent exchanges.
- Trial name
- NCT01459965
- Testing
- ERCP with 10 French biliary plastic stent placement, ERCP with 11.5 French biliary plastic stent
- Volunteers
- 164 people
- Sponsor
- Indiana University
Biliary Obstructive Disease Such as Choledocholithiasis, Benign Biliary Stricture
Effectiveness of Prophylactic Antibiotics to Prevent Post Endoscopic Retrograde Cholangio Pancreatography Bacteremia in Biliary Obstruction Patient
Endoscopic retrograde cholangio-pancreatography (ERCP) is advanced endoscopic technique that allows minimally invasive management of biliary and pancreatic disorders.
- Conditions
- Biliary Obstructive Disease Such as Choledocholithiasis, Benign Biliary Stricture, Peri-ampullary Cancer, Bile Duct Cancer Resectable
- Trial name
- NCT02958059
- Testing
- Pacetin® (cefoxitin)
- Where
- South Korea
- Volunteers
- 400 people
- Sponsor
- Yonsei University
Pancreaticobiliary Maljunction
Clinical Correlation Study Between Anomalous Pancreaticobiliary Ductal Junction and Malignant Tumors of the Biliary System and the Establishment of an AI-based Automated Recognition System
To explore the occurrence of pancreaticobiliary maljunction (PBM) in the Chinese population, the characteristics of various subtypes, and the relationship between PBM and malignant tumors of the biliary system.
- Trial name
- NCT06903520
- Where
- China
- Volunteers
- 2,439 people
- Sponsor
- Chinese PLA General Hospital